EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer

Klara Hammarström iD, Luís Nunes iD, Lucy Mathot iD, Artur Mezheyeuski iD, Emma Lundin iD, Nafsika Korsavidou Hult iD, Israa Imam iD, Emerik Osterlund iD, Tobias Sjöblom iD, Bengt Glimelius iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Klara Hammarström und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoplasm Recurrence, Local, Neoadjuvant Therapy, Mutation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rectal cancer poses challenges in preoperative treatment response, with up to 30% achieving a complete response (CR). Personalized treatment relies on accurate identification of responders at diagnosis. This study aimed to unravel CR determinants, overall survival (OS), and time to recurrence (TTR) using clinical and targeted sequencing data. Analyzing 402 patients undergoing preoperative treatment, tumor stage, size, and treatment emerged as robust response predictors. CR rates were higher in smaller, early‐stage, and intensively treated tumors. Targeted sequencing analyzed 216 cases, while 120 patients provided hotspot mutation data. KRAS mutation dramatically reduced CR odds by over 50% (odds ratio [OR] = 0.3 in the targeted sequencing and OR = 0.4 hotspot cohorts, respectively). In contrast, SMAD4 and SYNE1 mutations were associated with higher CR rates (OR = 6.0 and 6.8, respectively). Favorable OS was linked to younger age, CR, and low baseline carcinoembryonic antigen levels. Notably, CR and an APC mutation increased TTR, while a BRAF mutation negatively affected TTR. Beyond tumor burden, SMAD4 and SYNE1 mutations significantly influenced CR. KRAS mutations independently correlated with radiotherapy resistance, and BRAF mutations heightened recurrence risk. Intriguingly, non‐responding tumors with initially small sizes carried a higher risk of recurrence. The findings, even if limited in addition to the imperfect clinical factors, offer insights into rectal cancer treatment response, guiding personalized therapeutic strategies. By uncovering factors impacting CR, OS, and TTR, this study underscores the importance of tailored approaches for rectal cancer patients. These findings, based on extensive analysis and mutation data, pave the way for personalized interventions, optimizing outcomes in the challenges of rectal cancer preoperative treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNeoplasm Recurrence, LocalNeoadjuvant TherapyMutationSmad4 ProteinHumansMaleFemaleMiddle AgedAgedAdultProto-Oncogene Proteins p21(ras)Nerve Tissue ProteinsChemoradiotherapyAged, 80 and overTreatment OutcomeBiomarkers, TumorCytoskeletal ProteinsNuclear Proteins

Stichwörter der Autor:innen

complete remissionneoadjuvant therapyprognosisrectal cancerresponse prediction

Substanzen

Smad4 ProteinSMAD4 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Nerve Tissue ProteinsBiomarkers, TumorCytoskeletal ProteinsNuclear Proteins

Autor:innen und Institutionen

  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Klara Hammarström, Luís Nunes, Lucy Mathot, Artur Mezheyeuski, Emma Lundin, Nafsika Korsavidou Hult, Israa Imam, Emerik Osterlund, Tobias Sjöblom, Bengt Glimelius

Förderung

  • Cancerfonden

Zitieren

APA

Hammarström, K., Nunes, L., Mathot, L., Mezheyeuski, A., Lundin, E., Korsavidou Hult, N., Imam, I., Osterlund, E., Sjöblom, T., & Glimelius, B. (2024). Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34880

Vancouver

Hammarström K, Nunes L, Mathot L, Mezheyeuski A, Lundin E, Korsavidou Hult N, et al. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.34880

BibTeX
@article{Hammarstrm2024,
  author = {Hammarström, Klara and Nunes, Luís and Mathot, Lucy and Mezheyeuski, Artur and Lundin, Emma and Korsavidou Hult, Nafsika and Imam, Israa and Osterlund, Emerik and Sjöblom, Tobias and Glimelius, Bengt},
  title = {Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34880}
}
Kostenlos starten →